Labiotech.eu

News and Trends 14 Aug 2015

Milestone in Stem Cell Research: European Researchers grow Millimeter-Long Muscle Fibers!

Stem cell research grows and grows in Europe! For the first time ever, researchers succeded to effectively grow a large number of muscle cells derived from pluripotent stem cells! Researchers from six European countries are participating in the PluriMes project to give a cutting edge to the European stem cell research. Launched in February 2014, […]

August 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Aug 2015

Roche’s €382M Acquisition to Expand its Fight against Drug-Resistant Bacteria

The biggest biotech company worldwide has just become even bigger: Roche acquired the Californian GeneWEAVE BioSciences, a privately held company that developed a cool technology to diagnose drug-resistant bacteria. For the integration, Roche shells out $190M (€171M) upfront and up to $235M (€211M) product-related milestones. GeneWEAVE is an American company that developed a technology which is […]

August 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Aug 2015

It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund

Cash is floating into Biotech like never before, in the US as well as in Europe. And Woodford just announced he invested over 75% of the total money he raised, so over €800M. Let’s have a look at where the money went into. Neil Woodford is a legendary British Biotech investor who opened a new […]

August 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Aug 2015

Roche abandons Wilex to Make Way for Immuno-Oncology

Roche just dropped a first-generation antibody-based treatment preventing cancer cells from proliferating. Interestingly enough, the partner of the collaboration, Wilex’ subsidiary Heidelberg Pharma, stated the research “progressed well, on schedule, and in a mutually satisfactory manner”. What happened? Heidelberg Pharma is a German company that discovers new drugs using its platform technology for antibody drug […]

August 13, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 13 Aug 2015

Emmanuelle Charpentier, co-discoverer of CRISPR-Cas9 Technology, comes to Berlin!

French, young and brilliant, Emmanuelle Charpentier will now be working as a director at the Max Planck Institute for Infection Biology in Berlin! Emmanuelle Charpentier is labeled one of the most influential scientists by the Time magazine when she discovered THE new technology of the century: CRISPR-Cas9. Among numerous honors, she won the $3M Breakthrough Prizes […]

August 13, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

A Tale of Love for UniQure and Bristol-Myers Squibb

In May, Bristol-Myers Squibb (BMS) nailed down the exclusive access to uniQure’s gene therapy platform to treat cardiovascular diseases. Everything seems to work out fine as BMS paid $53M (€47M) for three new targets and additional shares to own nearly 10% of the company. UniQure is a Dutch pioneer in the field of gene therapy. It […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

Roche and Clovis combine drugs to fight lung cancer, the most common cancer worldwide

Roche‘s subsidiary Genentech joined forces with NASDAQ-listed Clovis Oncology to evaluate a novel combination therapy for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC). Its anti PD-L1 cancer immunotherapy and Clovis’ rociletinib will enter Phase Ib/II in 2015. With 1.35 million new cases annually, lung cancer is the most common cancer worldwide. In […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

CRISPR Therapeutics reinforces its Team with Top Executives from Pfizer and McKinsey

A new strategic movement in the hot CRISPR field: CRISPR Therapeutics ramps up its leadership team with Samarth Kulkarni as its new Chief Business Officer and Michael Bruce as Senior Vice President to moderate program portfolio and alliance management. In the meantime, CRISPR’s main competitor EditasMedicine procured €108M to accelerate its CRISPR-based therapies in clinical state. […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Aug 2015

18-year-old French Hybrigenics goes to the US with its Acute Myeloid Leukemia Treatment

Hybrigenics is one step closer to enter the American market. The FDA granted Orphan Drug designation to the company’s Acute Myeloid Leukemia (AML) Treatment. Currently in preclinical stage, the therapy showed efficacy in combination with two AML-drugs that are already approved. AML is the second most frequent form of leukemia and accounts for about 30% […]

August 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Aug 2015

Pili Printed their First Page with Bacteria-Made Ink!

Pili is a group of seven young dedicated entrepreneurs that dream of replacing the toxic pigments used in today’s ink with natural, non-toxic, recyclable ink made by bacteria. A dream that could soon become reality as the start-up just achieved the first proof of concept and printed its first page with a bacteria-made biodegradable ink! It […]

August 11, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 11 Aug 2015

AstraZeneca’s Oncology Expansion Continues: MedImmune grabs Inovio’s Cancer Vaccine

The massive expansion of AstraZeneca’s pipeline continues, as its biological subsidiary, MedImmune buys Inovio Pharmaceuticals‘ clinical-stage cancer vaccine that targets cancer caused by the human papillomavirus (HPV). MedImmune, which makes up nearly 50% of AstraZeneca’s pipeline, may spend over $720M (€653M) to bolster its cancer-associated portfolio. HPV is the most commonly sexually transmitted virus and […]

August 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

Oxitec’s revolutionary Genetically Modified Insects acquired by Intrexon for €146M

Oxitec‘s self-limiting gene technique, which is designed to exterminate dangerous insects, has a price now: $160M (€146M). US-based Intrexon absorbed the Oxford University’s spinout with its unique technology to accelerate the crackdown of dengue infections and crop damages. As we reported early this year, Intrexon Corporation recently partnered across diverse markets, all being part of […]

August 10, 2015 - 3 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Milestone in Stem Cell Research: European Researchers grow Millimeter-Long Muscle Fibers!

Roche’s €382M Acquisition to Expand its Fight against Drug-Resistant Bacteria

It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund

Roche abandons Wilex to Make Way for Immuno-Oncology

Emmanuelle Charpentier, co-discoverer of CRISPR-Cas9 Technology, comes to Berlin!

A Tale of Love for UniQure and Bristol-Myers Squibb

Roche and Clovis combine drugs to fight lung cancer, the most common cancer worldwide

CRISPR Therapeutics reinforces its Team with Top Executives from Pfizer and McKinsey

18-year-old French Hybrigenics goes to the US with its Acute Myeloid Leukemia Treatment

Pili Printed their First Page with Bacteria-Made Ink!

AstraZeneca’s Oncology Expansion Continues: MedImmune grabs Inovio’s Cancer Vaccine

Oxitec’s revolutionary Genetically Modified Insects acquired by Intrexon for €146M

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!